REGENXBIO research and develops adeno-associated viral gene therapies for treatment of lysosomal storage disorders and ocular diseases.
Business Model:
Revenue: $483.4M
Employees: 201-500
Address: 9804 Medical Center Drive
City: Rockville
State: MD
Zip: 20850
Country: US
REGENXBIO research and develops adeno-associated viral gene therapies for treatment of lysosomal storage disorders and ocular diseases.
Contact Phone:
+12405528181
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
9/8/2015
IPO Valuation:
$492M
Ticker Symbol:
RGNX
IPO Price:
$22/share
Amount Raised:
$138M
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Name | Price |
---|---|---|
8/2017 | Dimension Therapeutics |
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|